Lyell Immunopharma, Inc. (LYEL) – What Are Researchers Thinking About This Stock?

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $40.00.

LYEL has been the topic of several recent analyst reports. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, October 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, November 3rd. Stifel Nicolaus began coverage on Lyell Immunopharma in a research report on Thursday, August 6th. They set a “buy” rating and a $36.00 target price for the company. Royal Bank Of Canada set a $34.00 target price on shares of Lyell Immunopharma in a research report on Friday, August 14th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th.

Read Our Latest Stock Analysis on Lyell Immunopharma

Lyell Immunopharma Stock Up 1.6%

NASDAQ:LYEL opened at $13.80 on Friday. The company has a market capitalization of $339.34 million, a P/E ratio of -1.10 and a beta of -0.04. Lyell Immunopharma has a 52 week low of $7.20 and a 52 week high of $45.00. The stock’s fifty day moving average is $11.08 and its two-hundred day moving average is $16.14.

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.01) by $0.15. The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 107.62% and a negative net margin of 1,701,066.75%. Sell-side analysts anticipate that Lyell Immunopharma will post -6.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Lyell Immunopharma

In related news, major shareholder Arch Venture Partners Ix, Llc purchased 2,321,262 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was acquired at an average price of $10.77 per share, for a total transaction of $24,999,991.74. Following the purchase, the insider owned 3,747,790 shares of the company’s stock, valued at approximately $40,363,698.30. This trade represents a 162.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Venture Fund Xiii L.P. Arch purchased 2,321,262 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were purchased at an average cost of $10.77 per share, for a total transaction of $24,999,991.74. Following the completion of the transaction, the insider directly owned 3,747,790 shares of the company’s stock, valued at $40,363,698.30. This represents a 162.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have sold 2,100 shares of company stock worth $28,757. Corporate insiders own 6.20% of the company’s stock.

Institutional Trading of Lyell Immunopharma

A number of institutional investors have recently modified their holdings of LYEL. Renaissance Technologies LLC lifted its holdings in shares of Lyell Immunopharma by 194.8% in the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock worth $2,335,000 after buying an additional 76,921 shares in the last quarter. Opaleye Management Inc. grew its stake in Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after buying an additional 264,928 shares in the last quarter. venBio Partners LLC bought a new position in shares of Lyell Immunopharma in the 2nd quarter worth $4,744,643. Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma during the 1st quarter valued at $959,000. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma during the 1st quarter worth $445,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.

Featured Articles

Analyst Recommendations for Lyell Immunopharma (NASDAQ:LYEL)

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.